This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS).
LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study
by Zacks Equity Research
Lilly's muvalaplin significantly reduces elevated Lp(a) levels compared to placebo in a phase II study
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
by Zacks Equity Research
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
by Zacks Equity Research
AMGN says there was no connection between the administration of MariTide and bone mineral density changes.
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
by Kinjel Shah
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
by Kinjel Shah
AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
by Zacks Equity Research
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
Should Investors Buy Weakness in These High-Growth Stocks?
by Derek Lewis
Several popular stocks have seen negative post-earnings reactions, raising some questions. But should investors just block out the noise?
Stocks and ETFs in Focus as Americans Head to Polls
by Sweta Killa
Let's discuss the sectors and ETFs that are the potential gainers or losers as Americans head to the polls, which indicate a tight race between Harris and Trump.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?
by Kinjel Shah
Those who own Pfizer's stock may stay invested to see how Pfizer's new growth drivers perform.
Unlocking Lilly (LLY) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
by Kinjel Shah
LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.
Company News for Oct 31, 2024
by Zacks Equity Research
Companies In The Article Are:SMCI, LLY, ITW, CLH
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
by Zacks Equity Research
AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
by Zacks Equity Research
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.
ADP Higher Than Expected
by Zacks Equity Research
ADP Higher Than Expected
Goldilocks ADP Jobs Numbers, Q3 GDP and Earnings
by Mark Vickery
ADP private-sector payrolls for October came in at +253K, far ahead of the 113K expected.
Lilly (LLY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.